About Bio-Techne
Bio-Techne is a publicly listed company based in Minneapolis (United States) founded in 1981, and was acquired by Merck in June 2026. Developer of biotech reagents, instruments and clinical diagnostic products. The company has 3,100 employees. Bio-Techne has completed 17 acquisitions, including ACD Bio, Asuragen and Atlanta Biologicals. Its website bio-techne.com draws about 218 thousand monthly visits. Its Indian entity Bio-Techne India Private Limited reported revenue of ₹7.35 Cr. Bio-Techne offers products and services including Reagents and Kits, Analytical Instruments, and ELISA Kits. Its focus areas include Life Sciences, Life Sciences Platforms and Tools and Diversified. Its competitors include Bio Rad, Quanterix and Biocare Medical; 2 of its 3 listed competitors have raised funding.
Company details
Bio-Techne was founded in 1981 in Minneapolis, United States, within the biotechnology sector. Specialized proteins such as cytokines and growth factors are supplied, alongside antibodies, immunoassays, biologically active small molecules, and other reagents to research, diagnostics, and clinical control markets. Instrumentation is provided to streamline protein analysis processes for customers in these areas. Operations focus on supporting scientific and medical applications across the United States and internationally.
- Indian entity revenue₹7.35 Cr
FY 2024 · +9% YoY
- Indian entity net profit₹70.5 Lakh
FY 2024 · 10% margin
- Indian entity EBITDA₹1.10 Cr
FY 2024 · 15% margin
- Latest Funding Round$153K (USD), Grant
Jun 2016
- InvestorsMerck
& 1 more
- Employee Count3,100
- Investments & AcquisitionsACD Bio
& 16 more
- Acquired byMerck
(Jun 2026)
Associated legal entities of Bio-Techne
Bio-Techne operates through Bio-Techne India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Bio-Techne India Private Limited CIN U51909MH2017FTC302647 | Active | 08 Dec 2017 | Mumbai, Maharashtra | ₹7.4 Cr | 10 | 3 | View details |
Products & Services of Bio-Techne
Bio-Techne offers a comprehensive portfolio of products and services, including Reagents and Kits, Analytical Instruments, and ELISA Kits.
High-quality reagents for cell culture, assays, and protein analysis in scientific research.
Tools for immunoassays, protein analysis, and diagnostics in life sciences applications.
Kits for detecting and quantifying proteins in research and diagnostic settings.
Apps and channels of Bio-Techne
its YouTube channel Bio-Techne has 509 subscribers and 30 videos.
Videos from Bio-Techne
The most watched videos on Bio-Techne's YouTube channel, Bio-Techne (509 subscribers). Click a video to play it here.
More on Bio-Techne.
Funding Insights of Bio-Techne
- Total Rounds 6
- Last Round Grant — $152,999
- First Round $2.73M
(May 2009)
- Investors Count 1
All 6 funding rounds of Bio-Techne with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in Bio-Techne
Bio-Techne has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Merck and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Merck is engaged in science and technology solutions globally. | 1668 | merckgroup.com | Darmstadt, Germany |
Investor details for Bio-Techne
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Bio-Techne India Private Limited (Bio-Techne)
Bio-Techne India Private Limited is the primary company behind Bio-Techne. The board of Bio-Techne India Private Limited currently have 3 directors; the longest-serving is James Todd Hippel, appointed in 2017. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| James Todd Hippel DIN 07923425 | Director | 08 Dec 2017 | 8 yrs 10 mo | Bio-Techne India Private Limited |
| Anand Khetan DIN 07302683 | Director | 14 Mar 2019 | 7 yrs 7 mo | Bio-Techne India Private Limited |
| Shane Victor Bohnen DIN 10307300 | Director | 08 Sep 2023 | 3 yrs 2 mo | Bio-Techne India Private Limited |
People of Bio-Techne
414 people are tracked at Bio-Techne (96 in leadership, 318 in team); the tracked headcount is 3,100.
| Name | Role | Group |
|---|---|---|
Rachael Amato Assoc Cipd | HR Business Partner For EMEA | Leadership |
Ryan Dagon | Senior Director, Marketing Technology & Sales Enablement | Leadership |
Jen Souvignier | Global Director Of Commercial Training And Onboarding | Leadership |
Susan Plurad | Senior Manager, Field Applications - Immunoassay Business Unit Partner | Leadership |
| EVP & CFO | Leadership | |
Qi Cheng | VP, Quality & Regulatory | Leadership |
Marty Putnam | Vp, Immunoassay Technologies | Leadership |
Beth Sander | Director Of People | Leadership |
Lori Dawidowicz | Senior Director, Diagnostic Controls Business Unit | Leadership |
Johanne McGregor | Senior Director Of Marketing | Leadership |
Roberto Munoz | Director Of Quality | Leadership |
Michelle L. Collins | Senior Director, Corporate Development - Diagnostics & Genomics | Leadership |
Jim Hippel | Executive Vice President And Chief Financial Officer | Leadership |
Vincent Defrank | Director, Software Quality | Leadership |
Anonymous | VP, Global Human Resources | Leadership |
Erin Sheppard | Senior Manager, People Partner | Leadership |
Lindsey Rodger | Head Of Corporate Communications | Leadership |
Dawn Gast | Division Director, Bio-techne Diagnostics Division (bdd), Quality And Regulatory | Leadership |
Angela Chen | Vice President, Gm, APAC | Leadership |
Gaynor Worthington | HR Business Partner, EMEA | Leadership |
394 more people are available in the full profile.
Complete people profiles for Bio-Techne
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Bio-Techne
Bio-Techne is a publicly listed company on the NASDAQ with ticker symbol TECH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Feb 1989
- Listed onNASDAQ: TECH
- Listed entityBio-Techne Corp
- Exchange sectorHealth technology
- ISINUS09073M1045
- Share price$72.48 (-0.11% on the day) · 2026-10-13
- Market capitalisation$11.37B
- Price to earnings62.6
- EPS (diluted, trailing year)$1.16
- Dividend yield0.44%
- Volume (last session)2,420,572
Financials of Bio-Techne
Figures of Bio-Techne India Private Limited, the primary company behind Bio-Techne, for FY 2024. Revenue was ₹7.35 Cr (+9% year on year). Net profit was ₹70.5 Lakh (10% margin). EBITDA was ₹1.10 Cr (15% margin). Revenue has grown at a compounded annual rate of +1071% over three years and +28% over five years.
- ₹7.35 CrRevenue · FY 2024 · +9% YoY
- ₹70.5 LakhNet profit · 10% margin
- ₹1.10 CrEBITDA · 15% margin
- ₹1.98 CrPaid-up capital
- 10Employees (provident fund records)
- +1071%Revenue CAGR, 3 years
- +28%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | $1.22B | $181.8M | $372.8M |
| 2025 | $1.22B | $73.4M | $362.8M |
| 2024 | $1.16B | $168.1M | $386.7M |
| 2023 | $1.14B | $285.2M | $387.9M |
| 2022 | $1.11B | $271.9M | $377.6M |
Balance sheet, profit and loss, cash flow and ratios of Bio-Techne India Private Limited are on its company page.
Detailed financial statements for Bio-Techne
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bio-Techne
Bio-Techne has strategically engaged in corporate development activities, having acquired 17 companies. Notable acquisitions include ACD Bio, Asuragen and Atlanta Biologicals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Microfluidic-based instruments for tumor analysis are developed. | lunaphore.com | Morges, Switzerland | 2014 | Jun 2023 | •••• | |
Single-cell sorting instruments are developed using microfluidic technology. | namocell.com | Mountain View, United States | 2014 | Jun 2022 | •••• | |
Assays and kits developer for molecular diagnostics | asuragen.com | Austin, United States | 2006 | Mar 2021 | $215M | |
Developer of solutions for gene editing and gene delivery | bmogen.com | Minneapolis, United States | 2015 | Jun 2019 | •••• | |
Blood-based cancer diagnostics are developed for patient stratification and monitoring. | exosomedx.com | Boston, United States | 2008 | Jun 2018 | $250M | |
Cell isolation technologies are developed using biocompatible hydrogel platforms. | quadtechnologies.com | Woburn, United States | 2013 | Jun 2018 | •••• | |
Cell culture products including sera, media, and reagents are manufactured. | atlanta-biologicals.com | Flowery Branch, United States | 1992 | Jan 2018 | •••• | |
Products and services for cell biology research are provided. | trevigen.com | Gaithersburg, United States | 1992 | Sep 2017 | $11M | |
Developer of a transnational research platform for biomarker analysis | acdbio.com | Newark, United States | 2006 | Jul 2016 | $250M | |
Single-cell protein analysis tools are commercialized for research markets. | zephyrusbio.com | Berkeley, United States | 2013 | •••• |
Complete acquisition details for Bio-Techne
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Bio-Techne
15 dated milestones of Bio-Techne across 45 years, from founding to its latest funding, stage changes and deals.
- Founded Bio-Techne is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.7M.
- Funding Latest funding round, Grant, of $153K.
- Acquisition Acquires Spaceimportexport.
- Acquisition Acquires ACD Bio.
- Acquisition Acquires Trevigen.
- Acquisition Acquires Atlanta Biologicals.
- Acquisition Acquires Quad Technologies.
- Acquisition Acquires Exosome Diagnostics.
- Acquisition Acquires B-MoGen.
- Acquisition Acquires Asuragen.
- Acquisition Acquires Namocell.
- Acquisition Acquires Lunaphore.
- Exit Acquired by Merck.
Competitors of Bio-Techne
Bio-Techne has 3 listed competitors in our database, 2 of them funded. They include Bio Rad, Quanterix and Biocare Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bio-rad.com | 1952 | Hercules, United States | 10 | Portfolio of products and services for life science research and clinical diagnostic markets | ||
| quanterix.com | 2007 | Cambridge, United States | $99.5M | 141 | Assay kits for ultra-sensitive biomarker detection are developed. | |
| biocare.net | 1997 | Concord, United States | $85M | 161 | Primary antibodies and instruments for immunohistochemistry are manufactured. |
Detailed competitors of Bio-Techne
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bio-Techne
The website of Bio-Techne (bio-techne.com) receives about 218.1K visits a month.
- Monthly visits218.1K
▲ 15.4% vs previous month
Websites whose visitors overlap most with Bio-Techne. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| rndsystems.com | 100% | 349K | #159,292 | View details | |
| novusbio.com | 94% | 199.6K | #232,152 | View details | |
| biocompare.com | 91% | 244.1K | #187,636 | View details | |
| abcam.com | 86% | 602.8K | #91,958 | View details | |
| ptglab.com | 83% | #137,673 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Bio-Techne
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Bio-Techne (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bio-Techne
Complete news archive for Bio-Techne
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bio-Techne
Bio-Techne was founded in 1981 and raised its 1st funding round 28 years after it was founded.
Bio-Techne is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
Bio-Techne has 3,100 employees.
The primary company behind Bio-Techne, Bio-Techne India Private Limited, reported revenue of ₹7.35 Cr for FY 2024, up 9% year on year.
Bio-Techne was founded in 1981 in Minneapolis, United States, within the biotechnology sector. Specialized proteins such as cytokines and growth factors are supplied, alongside antibodies, immunoassays, biologically active small molecules, and other reagents to research, diagnostics, and clinical control markets. Instrumentation is provided to streamline protein analysis processes for customers in these areas. Operations focus on supporting scientific and medical applications across the United States and internationally.
Bio-Techne's top competitors include Biocare Medical, Quanterix and Bio Rad.
Bio-Techne offers Reagents and Kits, Analytical Instruments, and ELISA Kits.
Yes, Bio-Techne is publicly traded on NASDAQ under the ticker symbol TECH.
Bio-Techne has made 17 acquisitions, including ACD Bio, Asuragen, and Atlanta Biologicals.
Bio-Techne operates through Bio-Techne India Private Limited.
Yes. Bio-Techne was acquired by Merck in June 2026.